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perform the selection procedure for a set of patients. 
Subsequently, the choices are discussed in the group of 
observers and a set of selection rules is composed. In this 
lecture we will discuss the plan selection strategy for rectum 
cancer and its introduction in the clinic. 
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Purpose or Objective: Patients with hormone-resistant 
prostate cancer (PCa) have higher biochemical failure rates 
after radiation therapy. Cyclin D1 deregulated expression in 
PCa is associated with a more aggressive disease however its 
role in radioresistance has not been determined.  
 
Material and Methods: Cyclin D1 levels in the AR-negative, 
androgen-independent PC3 and AR-positive, androgen-
independent 22Rv1 cells were stably inhibited by transfection 
with Cyclin D1-short hairpin RNA (shRNA). Tumorigenicity and 
radiosensitivity were investigated using in vitro and in vivo 
experiments.  
 
Results: Independently by AR-expression, Cyclin D1 silencing 
interfered with PCa oncogenic phenotype by inducing growth 
arrest in the G1 phase of cell cycle and reducing soft agar 
colony formation, migration, invasion, tumor formation and 
neo-angiogenesis in xenografted mice. In vitro colony 
formation and in vivo tumor growth of the PCa xenografts 
were significantly inhibited by Cyclin D1 silencing combined 
with radiotherapy. Cyclin D1 silencing radiosensitizes PCa 
cells by impairing the NHEJ and HR pathways responsible of 
the DNA double-strand break repair. Cyclin D1 directly 
interacts with activated-ATM, -DNA-PKC and RAD51 that are 
downstream targets of Cyclin D1-mediated PCa cells 
radioresistance.  
 
Conclusion: Taken together, these observations suggest a 
Cyclin D1 role in radioresistance mechanism. Cyclin D1 could 
represents a potential target for radioresistent androgen-
sensitive or not prostate cancer cells. 
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Purpose or Objective: We investigated the effects of 
eukaryotic elongation factor 2 kinase (EEF2K) in esophageal 
squamous cell carcinoma (ESCC) and its role in radiosensivity. 
 
Material and Methods: We used quantitative real-time 
polymerase chain reaction and immunohistochemistry 
analyses to compare expression of EEF2K between paired 
ESCC samples and nontumor esophageal tissues. Lentivirus 
was used to overexpress and knockdown of EEF2K gene and 
stable transmitted cell line of ECA109 and TE13 were made. 
In vitro cell counting kit 8 and clone formation assay were 
used to detect cell viability and proliferation. Wound-healing 
migration assay, transwell invasion assay three-dimensional 
culture and tube formation assay were used to investigate 
invasion, metastasis and angiogenesis of ESCC. Radioresponse 
was primary examined by clone formation assay after 
exposure of 0, 2, 4, 6, 8 Gy X-ray by a medical accelerator of 
different stable cell lines. Then apoptosis, cell-cycle arrest, 
and γ-H2AX expression were examined in 0 Gy and 8 Gy in 
the overexpressed and knockdown ESCC cell line by flow 
cytometer and immunoflourence. Gene-chips and western 
blot were used to investigate molecular mechanism. In vivo 
experiments of xenografts were used to confirm the results. 
 
Results: Levels of eEF2K were increased 52.17% of ESCC 
samples compared with matched nontumor tissues, as well as 
ESCC cell lines. Increased levels of eEF2K were associated 
with ESCC survival times of patients (P<0.05). eEF2K 
expression correlated between tumor size and TNM stage in 
primary ESCC during clinicopathological feature analysis 
(P<0.05). EEF2K promotes ESCC proliferation and 
tumorgeneity in vitro and in vivo. Improved invasion, 
metastasis and angiogenesis were also seen in EEF2K 
overexpressed cells compared with control in TE13 and 
ECA109 cell lines. An improved radioresponse was detected in 
eEF2K knockdown cells which could also be induced by 
NH125, an eEF2K inhibitor. Affymetrix GeneChip were used in 
EEF2K overexpressed ECA109 and control cells in normal 
conditions and 8 Gy of irradiation and autophagy pathways 
were detected by bioinformatic analysis. Improved protein 
expression of Atg5, mTOR, LC3, and TP53 were confirmed by 
western blot. In xengraft radiosensivity experiments, an 
enhancement factor of 1.78 was seen in ECA109 bearing nude 
mouse by NH125, along with a reduction of tumor doubling 
time. Immunohistochemistry and immunofluorescence of 
tumor tissue confirmed the molecular mechanism of 
autophagy pathway. 
 
Conclusion: EEF2K is overexpressed in ESCC and associated 
with progression and shorter survival times of patients. 
Decreased expression of EEF2K correlated with a reduction of 
malignancy in biological behavior and an improvement of 
radioresistance in ESCC, which may be mediated by 
autophagy signaling pathway. Targeting EEF2K may be a 
potential therapeutic approach of ESCC in the future. 
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Purpose or Objective: Phosphatidylinositol 4-phosphate 
(PI4P), upstream regulator of both phospholipase C 
(PLC)/Protein Kinase C (PKC) and phosphatidylinositol 3-
kinase (PI3K) / serine/threonine-protein kinases (Akt) 
pathways which control the cell motility and proliferation, is 
produced by phosphatidylinositol 4-kinase (PI4K). Thus, an 
inhibition of PI4K could inactivate these two PI4P dependent 
pathways simultaneously. In this study, we tried to identify 
that which isotype of PI4K may affect a radiosensitivity using 
RNA interference (RNAi) and also to investigate anti-hepatitis 
C viral (HCV) agents which are known to inhibit PI4K activity, 
could be repositioned as a radiosensitizer in human breast 
cancer, glioblastoma and hepatoma models. 
 
Material and Methods: A panel of human cancer cell lines 
including U251 malignant glioma cells, BT474 breast cancer 
cells, and HepG2 hepatocellular carcinoma cells were used. 
RNAi was used to specific inhibition of each isotype of PI4K 
and clonogenic assay was performed to assess the 
radiosensitizing effect of each isotype. To select an anti-HCV 
agent for pharmacologic inhibition of PI4K, IC50s of nine 
commercial antiviral agents were determined. Specific 
inhibitory effect on PI4K isotype was determined by in vitro 
kinase assay. Radiosensitizing effect of the selected anti-HCV 
agents were tested by clonogenic assay in vitro and tumor 
xenograft model in vivo, respectively. Immunoblotting, 
immunocytochemistry, and invasion/migration assay were 
performed to identify the mechanism of radiosensitization. 
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Results: First, we identified that specific inhibition of PI4K 
IIIα using RNAi increased radiosensitivity in the human cancer 
cell lines we tested. In contrast, inhibition of other isotypes 
did not affect a radiosensitivity of these cancer cell lines. 
Next, in vitro kinase assays showed, simeprevir, a selected 
anti-HCV agent via IC50 assay, inhibited activity of PI4K IIIα in 
a dose-response manner. Pretreatment of simeprevir induced 
discernible downregulation of p-PKC and p-Akt and also 
increased clonogenic survival of U251, BT474, and HepG2 
cells in vitro and also significantly delayed growth of mouse 
tumor xenografts in vivo. Simeprevir caused prolongation of 
γH2AX foci after irradiation, decreased invasion / migration 
and downregulation of PD-L1 expression. 
 
Conclusion: Targeting PI4K IIIα using anti-HCV agent could be 
a viable drug repositioning approach to enhance the 
therapeutic efficacy of radiotherapy for breast cancer, 
glioblastoma and hepatoma. (Work supported by grant 
#2013R1A1A2074531 from the Ministry of Science, ICT & 
Future Planning to Kim IA) 
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Purpose or Objective: To investigate serial changes of tumor 
hypoxia in response to a single high dose irradiation by 
various clinical and pre-clinical methods in order to propose 
an optimal fractionation schedule for stereotactic ablative 
radiotherapy (SABR) 
 
Material and Methods: Syngeneic Lewis lung carcinomas 
were grown either orthotopically or subcutaneously in 
C57BL/6 mice and were irradiated with a single dose of 15 Gy 
to mimic SABR used in the clinic. Serial [18F]-misonidazole 
(F-MISO) positron emission tomography (PET) imaging, 
pimonidazole FACS analyses, hypoxia-responsive element 
(HRE)-driven bioluminescence, and Hoechst 33342 perfusion 
were performed before irradiation (d-1), at 6 hours (d0), 2 
(d2), and 6 days (d6) after irradiation for both subcutaneous 
and orthotopic lung tumors. For F-MISO, scan was performed 
2 hr after the intravenous injection of F-MISO probe and the 
tumor-to-brain ratio (TBR) was analyzed.  
 
Results: We observed that hypoxic signals were too low to 
quantitate for orthotopic tumors by F-MISO PET or HRE-driven 
bioluminescence imaging. In subcutaneous tumors TBR values 
were 2.87 ± 0.483 at d-1, 1.67 ± 0.116 at d0, 2.92 ± 0.334 at 
d2, and 2.13 ± 0.385 at d6, indicating that tumor hypoxia was 
decreased immediately after irradiation and returned to the 
pretreatment levels at d2, followed by a slight decrease by 
d6 post-radiation. Pimonidazole analysis also revealed similar 
patterns. By using Hoechst 33342 vascular perfusion dye and 
CD31 co-immunostaining, we found that there was a rapid 
and transient vascular collapse, which may have resulted in 
poor intratumoral perfusion of F-MISO PET tracer or 
pimonidazole delivered at d0 leading to decreased hypoxic 




Fig. 1. Temporal changes in tumor hypoxia for subcutaneous 
tumors by F-MISO PET imaging. (A) Representative PET 
images demonstrating F-MISO uptake in subcutaneous tumor. 
Arrows indicate the tumor position. (B) A graph showing TBR 
values for an individual animal. (C) A graph showing the mean 
± s.e.m. of TBR values (n = 5).  
 
Conclusion: We found tumor hypoxia levels to be returned to 
the pretreatment levels by 2 days after irradiation, hence 
supporting the current fractionation intervals of SABR being 
given at least 2 days. Our results also indicate that SABR may 
produce a rapid but reversible vascular collapse in tumors. 
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Purpose or Objective: In previous study we showed that 
γH2AX assay in ex vivo irradiated tumour samples collected 
from cancer patients of various types correlates with known 
differences in radioresponsiveness. In the present study we 
aimed to apply the assay in a panel of prostate tumour 
